{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:59:56Z","timestamp":1788447596832,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Combat Medical LTD"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide. Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients. Results: 66% are women and 34% are men with a median age of 59 years (range 17\u201386). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0\u201339), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo\u2013Clavien grade III\u2013IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0\u2013259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients. Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM.<\/jats:p>","DOI":"10.3390\/jcm12113774","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T02:27:30Z","timestamp":1685500050000},"page":"3774","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-1740","authenticated-orcid":false,"given":"Israel","family":"Manzanedo","sequence":"first","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Department of Surgery, Rey Juan Carlos University (URJC), 28933 Madrid, Spain"},{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-5112","authenticated-orcid":false,"given":"Fernando","family":"Pereira","sequence":"additional","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Department of Surgery, Rey Juan Carlos University (URJC), 28933 Madrid, Spain"},{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cascales-Campos","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Peritoneal Oncologic Surgery Unit, Department of Surgery, Hospital Virgen de la Arrixaca, IMIB-ARRIXACA, 30120 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Mu\u00f1oz-Casares","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of Surgery, Hospital Virgen del Roc\u00edo, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-9234","authenticated-orcid":false,"given":"Enrique","family":"Asensio","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Advanced Oncologic Surgery Unit, Department of General and Digestive Surgery, Hospital R\u00edo Hortega, 47012 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Torres-Melero","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital Universitario de Torrec\u00e1rdenas, 04009 Almer\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arancha","family":"Prada-Villaverde","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital Infanta Cristina, 06080 Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib\u00e1n","family":"Caravaca-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital General Universitario de Elche, 03203 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Guti\u00e9rrez-Calvo","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital Pr\u00edncipe de Asturias de Alcal\u00e1 de Henares, 28805 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Vaqu\u00e9","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital de La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Ortega","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital MD Anderson Cancer Center, 28033 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Titos-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital Regional Universitario de M\u00e1laga, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gonz\u00e1lez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"},{"name":"Department of General and Digestive Surgery, Hospital Insular, 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbalitz","family":"P\u00e9rez-Viejo","sequence":"additional","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Department of Surgery, Rey Juan Carlos University (URJC), 28933 Madrid, Spain"},{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Serrano","sequence":"additional","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Department of Surgery, Rey Juan Carlos University (URJC), 28933 Madrid, Spain"},{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6127-5118","authenticated-orcid":false,"given":"Beatriz","family":"Mart\u00ednez-Torres","sequence":"additional","affiliation":[{"name":"Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Department of Surgery, Rey Juan Carlos University (URJC), 28933 Madrid, Spain"},{"name":"Spanish Group of Peritoneal Oncologic Surgery (GECOP), 28001 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REGECOP Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07357907.2012.654871","article-title":"Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC\u2014Overview and basics","volume":"30","author":"Piso","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1245\/s10434-020-08208-z","article-title":"Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction","volume":"27","author":"Bhatt","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","article-title":"A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent","volume":"42","author":"Yonemura","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pereira, F., Serrano, A., Manzanedo, I., P\u00e9rez-Viejo, E., Gonz\u00e1lez-Moreno, S., Gonz\u00e1lez-Bay\u00f3n, L., Arjona-S\u00e1nchez, A., Torres, J., Ramos, I., and Barrios, M.E. (2022). GECOP-MMC: Phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09572-7"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jso.21068","article-title":"The intraoperative staging systems in the management of peritoneal surface malignancy","volume":"98","author":"Portilla","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jso.21072","article-title":"Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy","volume":"98","author":"Kusamura","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Glehen, O., Passot, G., Villeneuve, L., Vaudoyer, D., Bin-Dorel, S., Boschetti, G., Piaton, E., and Garofalo, A. (2014). GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-183"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1515\/pp-2021-0152","article-title":"Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: A systematic review","volume":"7","author":"Noiret","year":"2022","journal-title":"Pleura Peritoneum"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_21","unstructured":"Bernad\u00f3, M.I.R., Ma\u00f1a, O.C., Mart\u00edn-Baranera, M., and S\u00e1nchez, P.B. (Clin. Transl. Oncol., 2023). Morbimortality after 1321 consecutive CRS\u2009+\u2009HIPEC procedures: Seeking excellence in surgery for peritoneal surface malignancy, Clin. Transl. Oncol., Online ahead of print."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: A systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Arjona-S\u00e1nchez, A., Espinosa-Redondo, E., Guti\u00e9rrez-Calvo, A., Segura-Sampedro, J.J., P\u00e9rez-Viejo, E., Concepci\u00f3n-Mart\u00edn, V., S\u00e1nchez-Garc\u00eda, S., Garc\u00eda-Fadrique, A., Prieto-Nieto, I., and Barrios-Sanchez, P. (2023). Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial. JAMA Surg., e230662.","DOI":"10.1016\/j.ejso.2022.11.115"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Manzanedo, I., Pereira, F., P\u00e9rez-Viejo, E., and Serrano, \u00c1. (2023). Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment. Cancers, 15.","DOI":"10.3390\/cancers15061777"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.ejso.2021.05.016","article-title":"Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials","volume":"47","author":"Granieri","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1245\/s10434-021-11316-z","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages","volume":"29","author":"Zhang","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1245\/s10434-022-12312-7","article-title":"Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis","volume":"29","author":"Martins","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.21873\/anticanres.15857","article-title":"Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"42","author":"Rajha","year":"2022","journal-title":"Anticancer. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1245\/s10434-022-12990-3","article-title":"The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology","volume":"30","author":"Kusamura","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100945","DOI":"10.1016\/j.gore.2022.100945","article-title":"Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus","volume":"39","author":"Lok","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chicago Consensus Working Group, Izquierdo, F.J., Schuitevoerder, D., Plana, A., Eng, O.S., Sherman, S., Badgwell, B., Johnston, F.M., Abdel-Misih, S., and Blazer, D.G. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Cancer, 126, 2541\u20132546.","DOI":"10.1002\/cncr.32837"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3774\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:45:45Z","timestamp":1760125545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113774"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113774","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}